No profile data available.
Inventiva S.a. (IVA) is a healthcare company in the hepatic treatment pharmaceuticals industry, based in Daix, France, with about 87 full-time employees.
It reported revenue of 4.48 million EUR for fiscal year 2025, down 51.3% from fiscal year 2024, and net income of -354.14 million EUR. Its market capitalization was $746.46 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally.
Inventiva reported 4.48 million EUR in revenue for fiscal year 2025, down 51.3% from 9.20 million EUR in fiscal year 2024.
$746.46 million as of October 9, 2026.
Listed companies of a similar size in the same industry (hepatic treatment pharmaceuticals) include Madrigal Pharmaceuticals, Inc. (MDGL), Arrowhead Pharmaceuticals, Inc. (ARWR), Mirum Pharmaceuticals, Inc. (MIRM), Wave Life Sciences Ltd. (WVE).